Literature DB >> 22504106

Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients.

Abeer A Bahnassy1, Abdel-Rahman N Zekri, Amany A Abou-Bakr, Mervat M El-Deftar, Ahmad El-Bastawisy, Mona A Sakr, Ghada M El-Sherif, Rabab M Gaafar.   

Abstract

BACKGROUND: Malignant pleural mesothelioma (MPM) is a highly aggressive disease with a generally poor prognosis. Since escape from cell cycle checkpoint control is common in several solid tumors, the present study was performed to evaluate the role of some cell cycle regulatory genes in the development and progression of MPM. PATIENTS AND METHODS: Aberrant expression of p14(ARF), p16(INK4A), p21(waf), p27(KIP), p53, mdm2 and Rb was assessed in 55 MPM cases from Egypt using immunohistochemistry and PCR techniques. Results were correlated with clinico-pathological prognostic factors, overall and disease free survival (OS&DFS).
RESULTS: Altered expression of p14(ARF), p16(INK4A), p21(waf), p27(KIP1), Rb, p53 and mdm2 proteins was detected in 50.9%, 54.5%, 53.3%, 61.8%, 53.3%, 58.2%, and 50.8% of cases, respectively. SV40 infection significantly correlated with p14(ARF), 16(INK4A), p27(kip1) and Rb aberrations (p=0.014, p=0.02, p=0.01, p=-0.01). Asbestos exposure significantly correlated with p53, p21(waf) and mdm2 aberrations (p=0.001, p=0.03, p=0.02). On multivariate analysis PS ≥ 2, p27(KIP1) and Rb aberrations were independent prognostic factors for OS (p=0.016, p=0.011, p=0.003) whereas on tumor recurrence, p27(KIP1) and Rb aberrations were independent prognostic factors for DFS (p=0.002, p=0.03, p=0.01).
CONCLUSIONS: MPM is a complex disease characterized by multiple genetic aberrations; some of them involve cell cycle regulatory genes. p14(ARF), p16(INK4A), Rb and p27(KIP1) seem to be involved in SV40-associated MPM whereas mdm2, p53 and p21(WAF) are related to asbestos exposure. In addition to recurrence and PS, only p27(KIP1)and Rb could be used as molecular prognostic markers in MPM.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504106     DOI: 10.1016/j.yexmp.2012.04.001

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  7 in total

Review 1.  New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.

Authors:  Brooke T Mossman; Arti Shukla; Nicholas H Heintz; Claire F Verschraegen; Anish Thomas; Raffit Hassan
Journal:  Am J Pathol       Date:  2013-02-08       Impact factor: 4.307

2.  MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.

Authors:  R F H Walter; F D Mairinger; S Ting; C Vollbrecht; T Mairinger; D Theegarten; D C Christoph; K W Schmid; J Wohlschlaeger
Journal:  Br J Cancer       Date:  2015-02-10       Impact factor: 7.640

3.  Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.

Authors:  C J Jennings; B Murer; A O'Grady; L M Hearn; B J Harvey; E W Kay; W Thomas
Journal:  Br J Cancer       Date:  2015-06-09       Impact factor: 7.640

4.  CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.

Authors:  Eeva Kettunen; Sauli Savukoski; Kaisa Salmenkivi; Tom Böhling; Esa Vanhala; Eeva Kuosma; Sisko Anttila; Henrik Wolff
Journal:  BMC Cancer       Date:  2019-05-28       Impact factor: 4.430

5.  P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment.

Authors:  Federica Pezzuto; Francesca Lunardi; Luca Vedovelli; Francesco Fortarezza; Loredana Urso; Federica Grosso; Giovanni Luca Ceresoli; Izidor Kern; Gregor Vlacic; Eleonora Faccioli; Marco Schiavon; Dario Gregori; Federico Rea; Giulia Pasello; Fiorella Calabrese
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

6.  Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma.

Authors:  Umair Ali Khan Saddozai; Fengling Wang; Saadullah Khattak; Muhammad Usman Akbar; Muhammad Badar; Nazeer Hussain Khan; Lu Zhang; Wan Zhu; Longxiang Xie; Yongqiang Li; Xinying Ji; Xiangqian Guo
Journal:  Cells       Date:  2022-09-19       Impact factor: 7.666

7.  Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.

Authors:  Loredana Urso; Ilaria Cavallari; Micol Silic-Benussi; Lorena Biasini; Giulia Zago; Fiorella Calabrese; Pier Franco Conte; Vincenzo Ciminale; Giulia Pasello
Journal:  Oncotarget       Date:  2017-07-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.